Crescent Capital BDC, Inc. $CCAP Shares Sold by Denali Advisors LLC

Denali Advisors LLC trimmed its stake in shares of Crescent Capital BDC, Inc. (NASDAQ:CCAP) by 23.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,433 shares of the company’s stock after selling 36,258 shares during the quarter. Denali Advisors LLC’s holdings in Crescent Capital BDC were worth $1,675,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Catalyst Capital Advisors LLC acquired a new position in shares of Crescent Capital BDC during the second quarter worth about $69,000. Westbourne Investments Inc. purchased a new position in Crescent Capital BDC in the third quarter worth approximately $141,000. XTX Topco Ltd purchased a new position in Crescent Capital BDC in the second quarter worth approximately $165,000. Quantbot Technologies LP acquired a new position in Crescent Capital BDC during the 2nd quarter worth approximately $219,000. Finally, Catalina Capital Group LLC increased its position in shares of Crescent Capital BDC by 37.3% in the 3rd quarter. Catalina Capital Group LLC now owns 16,935 shares of the company’s stock valued at $241,000 after purchasing an additional 4,599 shares during the last quarter. Institutional investors and hedge funds own 49.46% of the company’s stock.

Crescent Capital BDC Stock Down 1.1%

Shares of NASDAQ CCAP opened at $13.97 on Tuesday. The business has a 50-day moving average price of $14.48 and a 200 day moving average price of $14.56. The stock has a market cap of $516.75 million, a PE ratio of 14.26 and a beta of 0.55. The company has a quick ratio of 1.20, a current ratio of 1.20 and a debt-to-equity ratio of 1.23. Crescent Capital BDC, Inc. has a 52-week low of $13.03 and a 52-week high of $20.19.

Analyst Upgrades and Downgrades

CCAP has been the subject of several recent analyst reports. Oppenheimer decreased their price objective on shares of Crescent Capital BDC from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Friday, November 14th. Keefe, Bruyette & Woods decreased their price target on Crescent Capital BDC from $17.00 to $15.50 and set an “outperform” rating for the company in a report on Friday, November 14th. Zacks Research upgraded Crescent Capital BDC from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 10th. Wall Street Zen raised Crescent Capital BDC from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, Wells Fargo & Company lowered their price target on Crescent Capital BDC from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.38.

Crescent Capital BDC Company Profile

Crescent Capital BDC, Inc is a closed-end, externally managed business development company that provides flexible financing solutions to middle market companies in the United States. Trading on the Nasdaq under the ticker CCAP, the firm offers investors exposure to a diversified portfolio of debt and equity instruments, targeting businesses with attractive risk-adjusted return profiles. Its primary objective is to generate current income through interest payments and potential capital appreciation via selective equity co-investments.

The company’s investment strategy emphasizes senior secured loans, unsecured second-lien loans, mezzanine debt, as well as preferred and common equity co-investments.